Article

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial

2022-10-13

Abstract excerpt

Cancer patients are at high risk of severe COVID-19 with high morbidity and mortality. Further, impaired humoral response renders SARS-CoV-2 vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized patien...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 638c0a11-f795-52af-94cb-9908c62d27f3
DOI: 10.1101/2022.10.10.22280850

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialDOI 10.1101/2022.10.10.22280850Read

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity Read

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity Read

Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsSemantic proximity Read

Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA VaccinesSemantic proximity Read

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancerSemantic proximity Read

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity Read

Challenges in the Clinical Management of SARS-CoV2-Infected Patients with Haematological MalignanciesSemantic proximity Read

Durable tracking anti-SARS-CoV-2 antibodies of cancer patients recovered from COVID-19Semantic proximity Read

Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity Read

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity Read

Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agentsSemantic proximity Read

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read